Overall Survival Benefits of Cancer Drugs Initially Approved by the US FDA Based on Surrogate Endpoints
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis
Lancet Oncol 2024 May 13;[EPub Ahead of Print], H Naci, Y Zhang, S Woloshin, X Guan, Z Xu, AK WagnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.